Bangladesh’s pharmaceutical industry is calling for an urgent review of the country’s medicine pricing policy, arguing that prolonged restrictions on price adjustments have eroded profitability and discouraged investment in new drug development.
Industry representatives warn that the current regulatory framework, which has limited price increases for years, is creating a financial environment where innovation becomes unsustainable.
The sector contends that without a mechanism to adjust prices in line with production costs and inflation, manufacturers face mounting pressure on margins.
The appeal comes as global tensions over pharmaceutical pricing frameworks intensify.
The United States recently launched a formal investigation into Germany’s pricing system, accusing the European nation of underpaying for innovative medicines.
Similarly, a report by the Grattan Institute in Australia highlighted concerns over opaque pricing arrangements that may disadvantage patients while benefiting intermediaries.